Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT ID: NCT00691964
Last Updated: 2013-01-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
347 participants
INTERVENTIONAL
2008-05-31
2009-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00710580
A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00570986
Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00292396
A Study of Safety and Efficacy Comparing ABT-874 Versus Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis
NCT00679731
Open Label Continuation Study in Moderate to Severe Psoriasis
NCT00626002
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
ABT-874
SQ injection 200 mg Weeks 0 and 4; 100 mg Week 8
B
etanercept
SQ injection 50 mg BIW
C
placebo
SQ placebo injections for ABT-874 and etanercept
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ABT-874
SQ injection 200 mg Weeks 0 and 4; 100 mg Week 8
etanercept
SQ injection 50 mg BIW
placebo
SQ placebo injections for ABT-874 and etanercept
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BSA 10%, PASI 12 or above, PGA 3 or above
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Paragon Biomedical
INDUSTRY
AbbVie (prior sponsor, Abbott)
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Martin Kaul, MD
Role: STUDY_DIRECTOR
AbbVie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site Reference ID/Investigator# 8458
Goodlettsville, Tennessee, United States
Site Reference ID/Investigator# 8478
Tucson, Arizona, United States
Site Reference ID/Investigator# 8462
Fresno, California, United States
Site Reference ID/Investigator# 8454
Los Angeles, California, United States
Site Reference ID/Investigator# 8476
Denver, Colorado, United States
Site Reference ID/Investigator# 9641
Miami, Florida, United States
Site Reference ID/Investigator# 8463
Alpharetta, Georgia, United States
Site Reference ID/Investigator# 8479
Arlington Heights, Illinois, United States
Site Reference ID/Investigator# 8527
Schaumburg, Illinois, United States
Site Reference ID/Investigator# 9001
Skokie, Illinois, United States
Site Reference ID/Investigator# 8466
West Dundee, Illinois, United States
Site Reference ID/Investigator# 8467
Indianapolis, Indiana, United States
Site Reference ID/Investigator# 8464
Boston, Massachusetts, United States
Site Reference ID/Investigator# 8459
St Louis, Missouri, United States
Site Reference ID/Investigator# 8473
East Windsor, New Jersey, United States
Site Reference ID/Investigator# 8457
New Brunswick, New Jersey, United States
Site Reference ID/Investigator# 8447
Albuquerque, New Mexico, United States
Site Reference ID/Investigator# 8475
New York, New York, United States
Site Reference ID/Investigator# 8468
Cincinnati, Ohio, United States
Site Reference ID/Investigator# 8460
Cleveland, Ohio, United States
Site Reference ID/Investigator# 9762
Oklahoma City, Oklahoma, United States
Site Reference ID/Investigator# 8480
Lake Oswego, Oregon, United States
Site Reference ID/Investigator# 8469
Portland, Oregon, United States
Site Reference ID/Investigator# 9566
Portland, Oregon, United States
Site Reference ID/Investigator# 9761
Hershey, Pennsylvania, United States
Site Reference ID/Investigator# 8471
Philadelphia, Pennsylvania, United States
Site Reference ID/Investigator# 8449
Johnston, Rhode Island, United States
Site Reference ID/Investigator# 8448
Providence, Rhode Island, United States
Site Reference ID/Investigator# 8456
Greer, South Carolina, United States
Site Reference ID/Investigator# 8461
Austin, Texas, United States
Site Reference ID/Investigator# 10542
Dallas, Texas, United States
Site Reference ID/Investigator# 8452
Houston, Texas, United States
Site Reference ID/Investigator# 8474
San Antonio, Texas, United States
Site Reference ID/Investigator# 8482
Tyler, Texas, United States
Site Reference ID/Investigator# 8472
Norfolk, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Gottlieb AB, Leonardi C, Kerdel F, Mehlis S, Olds M, Williams DA. Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol. 2011 Sep;165(3):652-60. doi: 10.1111/j.1365-2133.2011.10418.x. Epub 2011 Aug 4.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
M10-114
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.